Forootan Shiva S, Wong Yong-Chuan, Dodson Andrew, Wang Xianghong, Lin Ke, Smith Paul H, Foster Christopher S, Ke Youqiang
Molecular Pathology Laboratory, School of Cancer Studies, Faculty of Medicine, University of Liverpool, L69 3GA Liverpool, United Kingdom.
Hum Pathol. 2007 Sep;38(9):1321-9. doi: 10.1016/j.humpath.2007.02.011. Epub 2007 Jun 28.
The levels of Id-1 (inhibitor of DNA binding or inhibitor of cell differentiation) expression in a series of prostate cell lines and in an archival set of prostate tissues were examined. Western blot analysis showed that the level of Id-1 expressed in the androgen sensitive cell line LNCaP was 1.2 +/- 0.2 times that detected in the benign cell line PNT-2. The level of Id-1 increased further to 1.8 +/- 0.2 and 2.9 +/- 0.3 in the androgen-insensitive cell lines Du-145 and PC-3, respectively. Immunohistochemical staining with Id-1 antibody performed on 113 cases of prostate tissues showed that among the 7 normal cases, 6 (86%) stained either negative or weakly positive whereas only 1 (14%) stained moderately positive. Among the 36 benign prostatic hyperplasia (BPH) samples, 34 (94%) stained either negative or weakly positive; only 1 (3%) stained moderately and 1 (3%) stained strongly. Of the 70 carcinomas, 8 (11.5%) stained weakly, 34 (48.5%) stained moderately, and 28 (40%) stained strongly positive. The intensity of Id-1 staining in carcinomas was significantly stronger than that detected in the normal prostate and BPH (chi(2) test, P < .001) and it was significantly increased as the increasing malignancy of carcinomas measured by Gleason score (chi(2) test, P < .001). The intensity of Id-1 staining was partially associated with the levels of prostate-specific antigen, but not related to the level of androgen receptor. Kaplan-Meier survival curve analysis showed that, similar to Gleason scores, overexpression of Id-1 was significantly associated with the reduced length of patient survival (log-rank test, P = .01). These results suggest that Id-1 is a useful prognostic marker to predict the outcomes of patients with prostate cancer.
检测了一系列前列腺细胞系以及一组前列腺组织存档样本中DNA结合抑制因子或细胞分化抑制因子（Id-1）的表达水平。蛋白质免疫印迹分析显示，雄激素敏感细胞系LNCaP中Id-1的表达水平是良性细胞系PNT-2中检测到水平的1.2±0.2倍。在雄激素不敏感细胞系Du-145和PC-3中，Id-1水平进一步升高，分别为1.8±0.2和2.9±0.3。对113例前列腺组织进行Id-1抗体免疫组化染色显示，在7例正常病例中，6例（86%）染色为阴性或弱阳性，而只有1例（14%）染色为中度阳性。在36例良性前列腺增生（BPH）样本中，34例（94%）染色为阴性或弱阳性；只有1例（3%）染色为中度阳性，1例（3%）染色为强阳性。在70例癌组织中，8例（11.5%）染色为弱阳性，34例（48.5%）染色为中度阳性，28例（40%）染色为强阳性。癌组织中Id-1染色强度明显强于正常前列腺组织和BPH（卡方检验，P < 0.001），并且随着根据Gleason评分衡量的癌组织恶性程度增加而显著升高（卡方检验，P < 0.001）。Id-1染色强度与前列腺特异性抗原水平部分相关，但与雄激素受体水平无关。Kaplan-Meier生存曲线分析显示，与Gleason评分相似，Id-1的过表达与患者生存时间缩短显著相关（对数秩检验，P = 0.01）。这些结果表明，Id-1是预测前列腺癌患者预后的一个有用的预后标志物。
